2.2.0.25falsefalse001650 - Disclosure - Legal Proceedings and Contingenciestruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 4/3/2011
USD ($)
USD ($) / shares
$Cur_3mos_20110403http://www.sec.gov/CIK0000078003duration2011-01-01T00:00:002011-04-03T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDperShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PercentStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0us-gaap_CommitmentsAndContingenciesDisclosureAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_LegalMattersAndContingenciesTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left">
<a name="xbrlnote14"><b><u><font style="DISPLAY: inline; TEXT-DECORATION: underline">Note
14. Legal Proceedings and Contingencies</font></u></b></a>
</div>
<div style="display: block; text-indent: 0pt">
<br/>
</div>
<div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
of March 31, 2011, Pfizer and its affiliated companies had settled, or
entered into definitive agreements or agreements-in-principle to
settle, approximately one-third of the hormone-replacement therapy
actions pending against us and our affiliated companies. We have
recorded aggregate charges with respect to those actions, as well as
with respect to the actions that have resulted in verdicts against us
or our affiliated companies, of $172 million in the first quarter of
2011 and $300 million in previous quarters. In addition, we have
recorded a charge of $300 million in the first quarter of 2011 that
provides for the minimum expected costs to resolve all of the other
outstanding hormone-replacement therapy actions against Pfizer and its
affiliated companies, consistent with our current ability to quantify
such future costs. The foregoing charges are estimates and, while we
cannot reasonably estimate the maximum potential exposure or the range
of possible loss in excess of amounts accrued for these
contingencies given the uncertainties inherent in product liability
litigation, additional charges may be required in the future.</font>
</div>
<div style="display: block; text-indent: 0pt">
<br/>
</div>
<div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
January 2011, in a Multi-District Litigation (</font><i><font style="DISPLAY: inline; FONT-STYLE: italic">In
re Neurontin Antitrust Litigation</font></i><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
that consolidates three actions, the U.S. District Court for the
District of New Jersey certified a nationwide class consisting of
wholesalers and other entities who purchased Neurontin directly from
Pfizer and Warner-Lambert during the period from December 11, 2002
to August 31, 2008 and who also purchased generic gabapentin after it
became available.  The complaints allege that Pfizer and
Warner-Lambert engaged in anticompetitive conduct in violation of the
Sherman Act that included, among other things, submitting applications
for listing in the Orange Book and prosecuting and enforcing certain
patents relating to Neurontin, as well as engaging in off-label
marketing of Neurontin.  Plaintiffs seek compensatory damages, which
may be subject to trebling.</font>
</div>
</div>
</div>Note
14. Legal Proceedings and Contingencies
As
of March 31, 2011, Pfizer and itsfalsefalsefalsefalsefalseOthernonnum:textBlockItemTypenaThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.No authoritative reference available.falsefalse12Legal Proceedings and ContingenciesUnKnownUnKnownUnKnownUnKnownfalsetrue